[HTML][HTML] Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL—CALGB 150007/150012 …
LJ Esserman, DA Berry, A DeMichele… - Journal of Clinical …, 2012 - ncbi.nlm.nih.gov
Journal of Clinical Oncology, 2012•ncbi.nlm.nih.gov
Purpose Neoadjuvant chemotherapy for breast cancer provides critical information about
tumor response; how best to leverage this for predicting recurrence-free survival (RFS) is not
established. The I-SPY 1 TRIAL (Investigation of Serial Studies to Predict Your Therapeutic
Response With Imaging and Molecular Analysis) was a multicenter breast cancer study
integrating clinical, imaging, and genomic data to evaluate pathologic response, RFS, and
their relationship and predictability based on tumor biomarkers.
tumor response; how best to leverage this for predicting recurrence-free survival (RFS) is not
established. The I-SPY 1 TRIAL (Investigation of Serial Studies to Predict Your Therapeutic
Response With Imaging and Molecular Analysis) was a multicenter breast cancer study
integrating clinical, imaging, and genomic data to evaluate pathologic response, RFS, and
their relationship and predictability based on tumor biomarkers.
Abstract
Purpose
Neoadjuvant chemotherapy for breast cancer provides critical information about tumor response; how best to leverage this for predicting recurrence-free survival (RFS) is not established. The I-SPY 1 TRIAL (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging and Molecular Analysis) was a multicenter breast cancer study integrating clinical, imaging, and genomic data to evaluate pathologic response, RFS, and their relationship and predictability based on tumor biomarkers.
ncbi.nlm.nih.gov